Potiga, Trobalt(ezogabine)
Potiga (ezogabine) is a small molecule pharmaceutical. Ezogabine was first approved as Potiga on 2011-06-10. It is used to treat partial epilepsies in the USA. The pharmaceutical is active against potassium voltage-gated channel subfamily KQT member 5, potassium voltage-gated channel subfamily KQT member 3, potassium voltage-gated channel subfamily KQT member 2, and potassium voltage-gated channel subfamily KQT member 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| partial epilepsies | EFO_0004263 | D004828 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 4 | 1 | 12 | 2 | 5 | 24 |
| Seizures | D012640 | — | G40.4 | — | — | 8 | 2 | — | 10 |
| Partial epilepsies | D004828 | EFO_0004263 | — | 1 | — | — | 1 | 1 | 3 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Disease | D004194 | EFO_0000408 | R69 | — | — | 2 | — | — | 2 |
| Central nervous system diseases | D002493 | — | G96.9 | — | — | 2 | — | — | 2 |
| Brain diseases | D001927 | — | G93.40 | — | — | 2 | — | — | 2 |
| Nervous system diseases | D009422 | — | G00-G99 | — | — | 2 | — | — | 2 |
| Syndrome | D013577 | — | — | — | — | 2 | — | — | 2 |
| Epileptic syndromes | D000073376 | — | — | — | — | 2 | — | — | 2 |
| Lennox gastaut syndrome | D065768 | — | G40.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | — | 2 | — | — | — | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 2 | — | — | — | 2 |
| Neuralgia | D009437 | EFO_0009430 | — | — | 1 | — | — | — | 1 |
| Postherpetic neuralgia | D051474 | — | — | — | 1 | — | — | — | 1 |
| Anhedonia | D059445 | — | R45.84 | — | 1 | — | — | — | 1 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 1 | — | — | — | 1 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | — | — | — | 1 |
| Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary retention | D016055 | — | R33 | — | — | — | — | 1 | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ezogabine |
| INN | retigabine |
| Description | Ezogabine is a substituted aniline that is benzene-1,2,4-triamine bearing ethoxycarbonyl and 4-fluorobenzyl substituents at positions N-1 and N-4 respectively. An anticonvulsant used to treat seizures associated with epilepsy in adults. It has a role as an anticonvulsant and a potassium channel modulator. It is a carbamate ester, an organofluorine compound, a substituted aniline and a secondary amino compound. It is functionally related to a benzene-1,2,4-triamine. |
| Classification | Small molecule |
| Drug class | gabamimetics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N |
Identifiers
| PDB | — |
| CAS-ID | 150812-12-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL41355 |
| ChEBI ID | 68584 |
| PubChem CID | 121892 |
| DrugBank | DB04953 |
| UNII ID | 12G01I6BBU (ChemIDplus, GSRS) |
Target
Agency Approved
KCNQ5
KCNQ5
KCNQ3
KCNQ3
KCNQ2
KCNQ2
KCNQ4
KCNQ4
Organism
Homo sapiens
Gene name
KCNQ5
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily KQT member 5
Protein synonyms
KQT-like 5, potassium channel protein, Potassium channel subunit alpha KvLQT5, potassium channel, voltage gated KQT-like subfamily Q, member 5, Voltage-gated potassium channel subunit Kv7.5
Uniprot ID
Mouse ortholog
Kcnq5 (226922)
potassium voltage-gated channel subfamily KQT member 5 (Q9JK45)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,143 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
693 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use